ClinicalTrials.gg
CompletedNCT02182154Updated Jul 18, 2014

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

A Phase 1 interventional study of BIBF 1120 ES in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
21 Years to 55 Years
Sex
Male
01

Study summary

To assess the metabolic profile,

to obtain the mass balance after oral administration,

to determine the concentration of [14C]-radioactivity in blood cells, plasma, urine and faeces,

to determine BIBF 1120 and BIBF 1202 concentrations in plasma, urine, and faeces, if feasible,

to determine the protein binding of [14C]-radioactivity,

to determine the pharmacokinetics of BIBF 1120, BIBF 1202 and total radioactivity after a single oral administration of [14C]-BIBF 1120 in healthy volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects as determined by results of screening
  2. Signed written in accordance with GCP and local legislation
  3. Age ≥21 and ≤55 years
  4. ≥18.5 kg/m2 and ≤29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  2. History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  3. History of any major surgery within the last four weeks before participation in this study or any bone fracture within the last two months
  4. History of orthostatic hypotension, fainting spells and blackouts
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
  6. Chronic or relevant acute infections
  7. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  8. History of any bleeding disorder including prolonged or habitual bleeding, other haematologic disease or cerebral bleeding (e.g. after a car accident) or commotio cerebri
  9. Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
  10. Planned use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial
  11. Participation in another trial with an drug within 2 months prior to administration or during trial
  12. Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  13. Alcohol abuse (> 60 g/day)
  14. Drug abuse
  15. Blood donation within 1 month prior to administration or during the trial
  16. Excessive physical activities within 5 days prior to administration or during the trial
  17. Any laboratory value outside the reference range, unless considered to lack clinical reference
  18. Female gender
  19. Male subjects must agree to minimize the risk of female partners becoming pregnant from the dosing day until 3 months after the completion of the study. Acceptable methods of for male volunteers include a vasectomy no less than 3 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    BIBF 1120 ES

    Drug: BIBF 1120 ES

Interventions

06

What researchers measure

Primary outcomes

  1. [14C]-radioactivity in plasma and whole blood (C Blood cells/C plasma ratio of [14C]-radioactivity)

    Time frame: Up to 96 h after drug administration

  2. [14C]-radioactivity in urine

    Time frame: Up to 120 h after drug administration

  3. Measurement of the plasma protein binding of total [14C]-radioactivity in human plasma samples ex vivo

    Time frame: Up to 96 h after drug administration

  4. Maximum observed concentration of the analyte in plasma (Cmax)

    Time frame: Up to 96 h after drug administration

  5. Plasma concentration-time profiles of total radioactivity in whole blood and plasma

    Time frame: Up to 96 h after drug administration

  6. [14C]-metabolic profile and identification of metabolites in urine, in comparison with various animal species

    Time frame: Up to 120 h after drug aministration

  7. [14C]-radioactivity in faeces

    Time frame: up to 120 h after administration

  8. [14C]-metabolic profile and identification of metabolites in faeces, in comparison with various animal species

    Time frame: Up to 120 h after drug aministration

  9. [14C]-metabolic profile and identification of metabolites in plasma, in comparison with various animal species

    Time frame: Up to 96 h after drug aministration

  10. Time from dosing to peak concentration (tmax)

    Time frame: Up to 96 h after drug administration

  11. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: Up to 96 h after drug administration

  12. Terminal rate constant of the analyte in plasma (λz)

    Time frame: Up to 96 h after drug administration

  13. Area under the concentration-time curve of the analyte in plasma from zero time to 24 hours (AUC0-24)

    Time frame: Up to 24 h after drug administration

  14. Area under the concentration-time curve of the analyte in plasma from zero time to the time of the last quantifiable drug concentration (AUC0-tz)

    Time frame: Up to 96 h after drug administration

  15. Area under the concentration-time curve of the analyte in plasma from zero time to infinity (AUC0-∞)

    Time frame: Up to 96 h after drug administration

  16. Mean residence time of the analyte molecules in the body after oral administration (MRTpo)

    Time frame: Up to 96 h after drug administration

  17. Total clearance of the analyte in plasma following extravascular administration (CL/F)

    Time frame: Up to 96 h after drug administration

  18. Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)

    Time frame: Up to 96 h after drug administration

  19. Fraction of analyte eliminated in urine from 0 to the limit of the last quantifiable data point (fe0-tz)

    Time frame: Up to 96 h after drug administration

  20. Fraction of analyte eliminated in faeces from 0 to the limit of the last quantifiable data point (fe faeces,0-tz)

    Time frame: Up to 96 h after drug administration

  21. Amount of analyte that was eliminated in faeces from 0 to the limit of the last quantifiable data point (Ae faeces,0-tz)

    Time frame: Up to 96 h after drug administration

  22. Amount of analyte that was eliminated in urine from 0 to the limit of the last quantifiable data point (Ae0-tz)

    Time frame: Up to 96 h after drug administration

Secondary outcomes

  1. Change from baseline in vital signs

    Time frame: Baseline, day 14 after drug administration

  2. Change from baseline in routine laboratory

    Time frame: Baseline, day 14 after drug aministration

  3. Number of participants with adverse events

    Time frame: Up to day 14 after drug aministration

  4. Change from baseline in electrocardiogram

    Time frame: Baseline, day 14 after drug aministration

  5. Assessment of tolerability by investigator according a 4 point scale

    Time frame: Day 14 after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a primary completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Oct 2005
Primary completionActual
Nov 2005
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182154
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Oct 2005
Primary completion
Nov 2005
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion